(Q41312485)

29 September 2017

1 reference

title

Cytokines in autoimmunity (English)

1 reference

29 September 2017

Brennan FM

1

1 reference

29 September 2017

Feldmann M

series ordinal

2

1 reference

29 September 2017

publication date

1 December 1996

1 reference

Current Opinion in Immunology

29 September 2017

published in

1 reference

29 September 2017

volume

8

1 reference

29 September 2017

issue

6

1 reference

29 September 2017

page(s)

872-877

1 reference

Role of cytokines in rheumatoid arthritis

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: down-regulation of synovial T cells in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Multiple sclerosis: TNF revisited, with promise

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Processing of tumour necrosis factor-α precursor by metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Immunoregulatory role of interleukin 10 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Elevated interleukin-10 levels in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Interleukin-10 inhibition of the progression of established collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Interleukin-10-deficient mice develop chronic enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

IL-12: a key cytokine in immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Antibodies to interleukin 12 abrogate established experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

The role of IL-12 in the induction of organ-specific autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980018-5

7 January 2021

10.1016/S0952-7915(96)80018-5

Identifiers

DOI

1 reference

29 September 2017

1 reference